Rairig joins as Executive Vice President of Corporate Development to strengthen Psilera's business and commercial strategy
Tampa, Florida., September 4, 2025 /prnewswire/ -psilera, Inc. (“psilera”), a biotech company has been appointed to develop groundbreaking treatments for complex neurological disorders Scott W. Larry As executive vice president of corporate development. In this capacity, Raiigh oversees business development, investor relations, and commercialization strategies as the company moves its medication closer to the clinic.
“Scott's energy and passion for drug development adds him perfectly to his executive leadership team,” the doctor said. Chris WeukeeCEO of Psilera. “He was a dynamic and thoughtful leader and served as a catalyst to promote the innovative NeuroplusChaigen pipeline in addition to his team. His robust experience will help promote a mission to deliver medicines that change the way the world thinks.”
Raiigh joined Celgene and Bristol Myers Squibb's Psilera, and most recently served as the global commercial lead in precision medicine initiatives in oncology, hematology and neuroscience. Prior to this, Raiigh spent 17 years at Johnson & Johnson in leadership positions across the pharmaceutical and diagnostic segment, providing personalized medicine solutions in several therapeutic areas, including brain health, focusing on Alzheimer's and depression. Rairig's career was formed from the foundations of a Bachelor of Science degree. Towson University And Master's degree in science Johns Hopkins University As well as the leadership certificate from Harvard Business School.
“This expanded role at Psilera will enable us to serve patients and families more meaningfully,” Raiigh said. “Since joining the board in 2019, I have been totally impressed with Dr. von Salm, Dr. Witowski, and the entire Cyrera team. Their commitment to providing medications in the class that rewire and activate neural pathways targeting dementia, addiction, and other brain health challenges is extraordinary.”
About Psilera:
Psilera is a biotechnology research and development company founded to create medicines that change the way the world thinks. By exploiting the potential of natural products, the company advances neuroplastic therapy to help patients suffering from neurodegeneration and addiction. Psilera has accumulated a major pipeline of next-generation assets, including PSIL-006, the first-class therapeutic agent for the treatment of frontotemporal dementia (FTD). For more information about this new era of mindful medicine, visit www.psilera.com.
Media Contact:
Psilera Inc.
Michael Lauer
MDL Strategic Communication
(Email protection)
Source: Psilera, Inc.
